Mondego Bio Selects PTPN2 Inhibitor, Targets First Trials in 2026
Mondego Bio, a clinical-stage biotechnology company developing next-generation small-molecule immuno-oncology therapies, today announced the formal selection of its lead clinical candidate, ZE00-0388, a highly selective...